Skip to main content
. 2024 Aug 20;65(10):26. doi: 10.1167/iovs.65.10.26

Figure 5.

Figure 5.

In vivo drug screening of zebrafish xenografts. (A) Normalized tumor burden of 92.1-xenografts after 3 days of treatment with DMSO (n = 21), ricolinostat (n = 22), quisinostat (n = 25), or their combination (n = 33). (B) Average cell dissemination distance of treated 92.1-xenografts. (C) Number of disseminated cells in treated 92.1-xenografts. (D) Normalized tumor burden of Mel202-xenografts after 3 days of treatment with DMSO (n = 21), E7107 (n = 19), withaferin A (n = 20), or the combination of both (n = 23). (E) Average cell dissemination distance of treated Mel202-xenografts. (F) Number of disseminated cells in treated Mel202-xenografts. (G) Normalized tumor burden of MP46-xenografts after 3 days of treatment with DMSO (n = 19), ricolinostat (n = 20), quisinostat (n = 20), or their combination (n = 20). (H) Average cell dissemination distance of treated MP46-xenografts. (I) Number of disseminated MP46-xenograft-bearing cells.